China Opens Up Non-End-To-End Manufacturing Of Biologics Within, Across Border

China implements a new pilot scheme allowing non-end-to-end manufacturing of certain biologics before possible nationwide implementation for all such products, with resource optimization and aligned quality management systems among the main goals.